TSI introduces the BioTrak™ Real-Time Viable Particle Counter for monitoring pharmaceutical cleanroom facilities.
TSI Incorporated Introduces Innovative Solution for Real-time Viable Particle Detection
TSI introduces the BioTrak Real-Time Viable Particle Counter for monitoring pharmaceutical cleanroom facilities. This unique product detects airborne viable particles utilizing TSI’s patented fluorescence detection technology, based on TSI’s 20 years experience of biological threat detection instrumentation. By minimizing false positives, the BioTrak Particle Counter delivers more confidence in instant detection and identification of viable particles to Quality Assurance Professionals.
In addition, the BioTrak Particle Counter measures traditional airborne particle counts, at 1.0 CFM, fully compliant to ISO-21501-4. The instrument simultaneously displays and data logs viable and non-viable airborne particle counts. The BioTrak Particle Counter provides end users with meaningful data to detect unwanted events and support root cause investigations.
TSI’s President, Tom Kennedy, stated, "We're excited to announce the launch of the BioTrak Particle Counter, which incorporates TSI’s patented fluorescence technology, to the underserved market for accurate, real-time viable detection in life science cleanrooms."
For more information, visit: www.tsi.com/biotrak.
##
About TSI Incorporated
TSI Incorporated serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. With headquarters based in the U.S. and field offices throughout Europe and Asia, TSI has established a worldwide presence in the markets we serve. Every day, our dedicated employees turn research into reality.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.